Dr. Nathalie McDowell Johnson, M.D., FACS, surgical oncologist and immediate past president of the American Society of Breast Surgeons shares her insight and opinion regarding racial disparities for Black women with breast cancer and the call to action for the medical community to consider using the 150-gene assay (Agendia) to provide a more comprehensive understanding and accurate risk assessment than the 21-gene assay, stating: “Knowing that the 21-gene recurrence score underestimates risk for Black patients, more institutions need to offer genomic tests that will give every patient an accurate risk evaluation, more appropriate and personalized treatment choices, and better outcomes.” Click to Read the Full Article